Amphetamine Amino Acid Conjugates for Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current amphetamine treatments suffer from rapid blood concentration spikes leading to undesirable side effects such as cardiovascular stress, behavioral deterioration, and high abuse potential due to their fast-acting nature, which limits their therapeutic efficacy and increases the risk of addiction.
Innovation Solution
Development of non-standard amino acid conjugates of amphetamine that are converted into their active form in the body, providing controlled and sustained release, reducing blood level spikes and abuse liability through oral bioavailability while maintaining therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If fast-acting amphetamine formulations are used, then rapid therapeutic effect is achieved, but blood concentration spikes occur leading to cardiovascular stress and abuse potential
Solution Approach 1:
The amphetamine is pre-conjugated with a polar hydrophilic group (such as amino acid moieties) before administration to create a prodrug form that is pharmacologically inactive or less active until metabolized in the body. This preliminary chemical modification ensures that the active amphetamine is released gradually through metabolic processes rather than appearing rapidly in blood, thus preventing concentration spikes while maintaining therapeutic efficacy.
Solution Approach 2:
A polar hydrophilic intermediary group (amino acid conjugate) is introduced between the amphetamine molecule and the biological system. This intermediary acts as a controlled-release vehicle that modulates the release kinetics of amphetamine through hydrolysis or metabolic cleavage, preventing direct rapid absorption and subsequent harmful effects while still delivering the therapeutic agent.
2Object-affected harmful factors
If sustained release formulations are developed, then blood level spikes are reduced, but therapeutic efficacy duration must be maintained
Solution Approach 1:
The chemical structure of amphetamine is modified by conjugating with polar hydrophilic groups (amino acids), which fundamentally changes its pharmacokinetic parameters. This structural modification alters absorption, distribution, metabolism, and excretion characteristics to achieve sustained release without requiring complex formulation technologies, thereby maintaining therapeutic efficacy over extended periods while preventing blood level spikes.
Solution Approach 2:
The amphetamine is combined with polar hydrophilic amino acid moieties to create a composite prodrug molecule. This composite structure leverages the properties of both components: the amphetamine provides therapeutic activity while the amino acid conjugate controls release kinetics through its polar hydrophilic characteristics and metabolic stability, achieving sustained therapeutic effect without harmful spikes.
3Object-affected harmful factors
If prodrug forms are used, then abuse potential is reduced, but manufacturing complexity increases
Solution Approach 1:
The amphetamine molecule is segmented by attaching separate amino acid moieties through conjugation. This segmentation creates distinct functional regions: the amphetamine core for therapeutic activity and the amino acid conjugate for controlled release. The modular nature of this segmentation allows for relatively straightforward synthesis through established conjugation chemistry, avoiding overly complex manufacturing processes while achieving abuse-deterrent properties.
Data Source
AI summary
Disclosed are polar, hydrophilic stimulant prodrug compositions comprising at least one stimulant chemically attached to a polar hydrophilic ligand, a salt thereof, a derivative thereof, or a combination thereof. Also disclosed are non-standard amino acid conjugates of amphetamine. Methods of making and using the same are also disclosed.